Adjust Font Size:

Press Releases

Advanced Cell Presents Phase I (b) Data Demonstrating Safety and Optimal Dosage for Myoblast Program at TCT Conference and Exposition

LOS ANGELES-- (BUSINESS WIRE)--Advanced Cell Technology, Inc. (OTCBB: ACTC - News) announced today that Dr. Nabil Dib presented interim, 6 month safety and dosage data for ACT's Myoblast Phase I (b) Program at TCT 2007 - the Transcatheter Cardiovascular Therapeutic Conference and Exposition, in Washington D.C. from October 20-25, 2007. TCT is one of the leading conferences for the field of interventional cardiology. The interim data showed myoblast safety, with no evidence for increased risk of arrhythmia. The safety data presented by Dr. Dib distinguish the ACT Myoblast Program, which in contrast to other clinical programs does not require the use anti-arrhythmia medications and/or an implanted defibrillator device.

Further, as noted by Dr. Dib, the current study provides support for the hypothesis that myoblasts can help repair scarred myocardium.This was achieved by use of a control group and echocardiology core lab analysis. Dr. Dib presented the six-month interim data at "Interventional Heart Failure II: Endovascular and Surgical Approaches Session IV: Abstract session-therapeutics in heart failure.. "I am pleased that we were selected to participate in this high-profile event” said Dr. Jonathan Dinsmore, Ph.D. "Our highly experienced clinical and cell manufacturing teams have demonstrated that through years of research we have achieved a superior safety profile enabling us to conduct all of our trials without the need for assist devices or arrhythmia preventative drugs. Our continuing safety results should provide for the most effective development of the myoblast technology through upcoming larger efficacy studies.

TCT 2007 is the essential gathering place for physicians, allied healthcare professionals, academics, and regulators to review critically and openly the status of cardiovascular intervention and to chart pathways to further improve outcomes for patients with coronary, endovascular, and structural heart disease.

Advanced Cell Technology's myoblast therapy (acquired via its acquisition of Mytogen, Inc.) involves the transplantation of expanded autologous myoblasts (adult progenitor stem cells) derived from a small biopsy of skeletal muscle from a patient's leg. The technology allows for the expansion of myoblasts into hundreds of millions of cells over a period of two to three weeks. The resulting myoblasts are then transplanted back into the patient's scarred heart tissue through the use of a 3-D electromechanical mapping based-catheter procedure, which differs from a number of competitive therapies that may require open heart surgery or a less precise catheter-based system to deliver new cells.

About TCT 2007

With rapid changes occurring in the field of interventional vascular medicine, TCT 2007 will be the essential gathering place for physicians, allied healthcare professionals, academics, and regulators to review critically and openly the status of cardiovascular intervention and to chart pathways to further improve outcomes for patients with coronary, endovascular, and structural heart disease.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.

For more information, visit "www.advancedcell.com":http://www.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

Contact

Media:
Chad Griffin Consulting, Inc.
Jordan Markwith, 310-888-3523

Investors:
CEOcast, Inc.
Andrew Hellman, 212-732-4300

Press Contact


Jordan Markwith
310-888-3523

Download PDF


10.25.07.pdf

To view PDF Files, you must have Acrobat Reader.

Download Adobe Acrobat